SEGMENT INFORMATION

6 Months Ended

Mar. 31, 2021

SEGMENT INFORMATION

SEGMENT INFORMATION

5.           SEGMENT INFORMATION

The Company operates in two principal segments - research services and research products. The Services segment provides research and development support on a contract basis directly to pharmaceutical companies. The Products segment provides liquid chromatography, electrochemical and physiological monitoring products to pharmaceutical companies, universities, government research centers and medical research institutions.  The accounting policies of these segments are the same as those described in the summary of significant accounting policies found in Note 2 to the Consolidated Financial Statements in the Company’s annual report on Form 10-K for the fiscal year ended September 30, 2020.

	Three Months Ended				Six Months Ended
	March 31,				March 31,
	2021		2020		2021		2020
Revenue:
Service	$	17,902	$	15,191	$	34,934	$	27,333
Product		849		821		1,702		1,597
	$	18,751	$	16,012	$	36,636	$	28,930
Operating Income (Loss)
Service	$	3,794	$	2,575	$	6,905	$	3,933
Product		(26)		(200)		141		(470)
Corporate		(4,289)		(2,570)		(7,553)		(4,678)
	$	(521)	$	(195)	$	(507)	$	(1,215)
Interest expense		(366)		(392)		(713)		(703)
Other income		179		10		179		12
Loss before income taxes	$	(708)	$	(577)	$	(1,041)	$	(1,906)